Interstitial Lung Disease Trial, Recruiting (NCT04304898)

Interstitial Lung Disease Trial, Recruiting NCT04304898 Sponsor: Erasmus Medical Center Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT04304898 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

You must have been recently diagnosed with a specific type of scarring lung disease (called fibrotic interstitial lung disease, or F-ILD), confirmed by a team of specialists using recognised medical guidelines
Your diagnosis must have been made no more than 6 months before joining the trial
You must have been receiving treatment for this lung condition for no longer than 1 month

Who may not be able to join:

You may not be able to join if you are not able to speak, read, or write in the main language of the country where the trial is taking place
You may not be able to join if the trial team believes, or you feel yourself, that you would not be able to follow the trial's rules and requirements
You may not be able to join if you do not have access to the internet

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marlies Wijsenbeek, MD PhD, Erasmus Medical Center

Phone: +31107030323

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04304898

Sponsor: Erasmus Medical Center

Phase: Not Applicable

Status: Recruiting

Condition: Interstitial Lung Disease

Trial contact: +31107030323

More information: https://clinicaltrials.gov/study/NCT04304898

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

"Who might be able to join this trial:

You must have been recently diagnosed with a specific type of scarring lung disease (called fibrotic interstitial lung disease, or F-ILD), confirmed by a team of specialists using recognised medical guidelines
Your diagnosis must have been made no more than 6 months before joining the trial
You must have been receiving treatment for this lung condition for no longer than 1 month

Who may not be able to join:

You may not be able to join if you are not able to speak, read, or write in the main language of the country where the trial is taking place
You may not be able to join if the trial team believes, or you feel yourself, that you would not be able to follow the trial's rules and requirements
You may not be able to join if you do not have access to the internet

Important: Always verify eligibility with the trial site directly before applying."

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Erasmus Medical Center

Registry

ClinicalTrials.gov

Start date

1 May 2020

Est. completion

1 July 2025

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Forced Vital Capacity (FVC) home spirometry; Forced Vital Capacity (FVC) home spirometry; Forced Vital Capacity (FVC) home spirometry; Forced Vital Capacity (FVC) hospital spirometry; Forced Vital Capacity (FVC) hospital spirometry; Forced Vital Capacity (FVC) hospital spirometry; Adherence to daily home spirometry; Adherence to weekly home spirometry; L-PF Impacts; K-BILD; EQ5D; VAS; LCQ; FAS; WPAI; GRoC; L-PF Impacts; K-BILD; EQ5D; VAS; LCQ; FAS; WPAI; GRoC; L-PF Impacts; K-BILD; EQ5D; VAS; LCQ; FAS; WPAI; GRoC; Time to change of L-PF Impacts; Time to change of K-BILD; Time to change of EQ5D...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov